^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    autologous 3rd generation CD19-targeting CAR T cell therapy

    i
    Other names: autologous 3rd generation CD19-targeting CAR T cell therapy
    Associations

    News

    Trials
    Company:
    Uppsala University
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over2years
    CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy (clinicaltrials.gov)
    P2, N=24, Completed, Uppsala University | Active, not recruiting --> Completed | Trial completion date: Apr 2022 --> Aug 2021 | Trial primary completion date: Apr 2022 --> Aug 2021
    Trial completion • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    autologous 3rd generation CD19-targeting CAR T cell therapy